De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. Bryant AK, Sankar K, Zhao L, Strohbehn GW, et al. Eur J Cancer 2022;171:55-63.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bryant AK, Sankar K, Zhao L, Strohbehn GW, et al. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. Eur J Cancer 2022;171:55-63.
PMID: 35704975